SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination - Quiz - MDSpire

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

  • By

  • José Luis Piñana

  • Rodrigo Martino

  • Lourdes Vazquez

  • Lucia López-Corral

  • Ariadna Pérez

  • Pedro Chorão

  • Alejandro Avendaño-Pita

  • María-Jesús Pascual

  • Andrés Sánchez-Salinas

  • Gabriela Sanz-Linares

  • María T. Olave

  • Ignacio Arroyo

  • Mar Tormo

  • Lucia Villalon

  • Venancio Conesa-Garcia

  • Beatriz Gago

  • María-José Terol

  • Marta Villalba

  • Valentín Garcia-Gutierrez

  • Almudena Cabero

  • José Ángel Hernández-Rivas

  • Elena Ferrer

  • Irene García-Cadenas

  • Anabel Teruel

  • David Navarro

  • Ángel Cedillo

  • Anna Sureda

  • Carlos Solano

  • February 28, 2023

  • 0 min

Share

Original Source(s)

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

  • by José Luis Piñana, Rodrigo Martino, Lourdes Vazquez, Lucia López-Corral, Ariadna Pérez, Pedro Chorão, Alejandro Avendaño-Pita, María-Jesús Pascual, Andrés Sánchez-Salinas, Gabriela Sanz-Linares, María T. Olave, Ignacio Arroyo, Mar Tormo, Lucia Villalon, Venancio Conesa-Garcia, Beatriz Gago, María-José Terol, Marta Villalba, Valentín Garcia-Gutierrez, Almudena Cabero, José Ángel Hernández-Rivas, Elena Ferrer, Irene García-Cadenas, Anabel Teruel, David Navarro, Ángel Cedillo, Anna Sureda, Carlos Solano

  • February 28, 2023

Related Content

Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan

Mendelian Randomization and Infection: Pitfalls and Promises

Generalizability of anti–SARS-CoV-2 seroprevalence estimates to the Montréal pediatric population: a comparison between 2 weighting methods